There are currently 2033 clinical trials in Los Angeles, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Cedars-Sinai Medical Center, USC Norris Comprehensive Cancer Center, Children's Hospital Los Angeles and University of California Los Angeles. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Movement and Fitness Trackers in Determining Performance Status
NCT03971266
Recruiting
This trial studies the use of movement and fitness trackers in determining performance status of patients with cancer who are taking part in early phase clinical. Movement and fitness trackers record movement and a number of different metrics such as steps, heart rate, and calories burned. The use of movement and fitness trackers can provide a more objective and precise estimate of patient performance status and help identify those most at risk for adverse events and hospitalization.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: Los Angeles County-USC Medical Center, Los Angeles, California +1 locations
Conditions: Malignant Neoplasm
Register for Updates
A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis
NCT05862272
Recruiting
The purpose of this clinical trial to characterize changes in bone mineral density during continuous treatment with relugolix combination tablet for up to 48 months (4 years) and 1 year of post-treatment follow-up in premenopausal women with heavy menstrual bleeding associated with uterine leiomyomas (fibroids) or with moderate-to-severe pain associated with endometriosis.
Gender:
Female
Ages:
Between 18 years and 50 years
Trial Updated:
03/14/2024
Locations: Los Angeles, Los Angeles, California
Conditions: Uterine Fibroids, Endometriosis
Register for Updates
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT05348577
Recruiting
This study will assess the efficacy and safety of capivasertib plus docetaxel versus placebo plus docetaxel in participants with metastatic castration resistant prostate cancer (mCRPC), all participants will receive the docetaxel with steroid therapy and receive androgen deprivation therapy. The intention of the study is to demonstrate that the combination of capivasertib plus docetaxel is superior to placebo plus docetaxel with respect to the overall survival of study participants, when overall... Read More
Gender:
Male
Ages:
Between 18 years and 130 years
Trial Updated:
03/14/2024
Locations: Research Site, Los Angeles, California
Conditions: Prostate Cancer
Register for Updates
FID-007 in Treating Participants With Advanced Solid Tumors
NCT03537690
Recruiting
This phase I trial studies the side effects and best dose of PEOX-based polymer encapsulated paclitaxel FID-007 (FID-007) in treating participants with malignant neoplasms that have spread to other places in the body and do not respond to treatment. FID-007 is a packaged form of the chemotherapy drug paclitaxel, and uses a polyethylozaxoline (PEOX) polymer which may allow the drug to reach deeper into tumors and less into normal cells by being smaller.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: Los Angeles General Medical Center, Los Angeles, California +1 locations
Conditions: Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Register for Updates
Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The C-TRACT Trial)
NCT03250247
Recruiting
The purpose of this study is to determine if the use of image-guided, endovascular therapy (EVT) is an effective strategy with which to reduce Post Thrombotic Syndrome (PTS) disease severity and improve quality of life in patients with established disabling iliac-obstructive post thrombotic syndrome (DIO-PTS).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: UCLA, Los Angeles, California
Conditions: Deep Vein Thrombosis, Venous Stasis, Venous Insufficiency, Venous Leg Ulcer, Venous Reflux, Post Thrombotic Syndrome
Register for Updates
Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)
NCT05231668
Recruiting
SAR439459 is a human anti-Transforming growth factor β (TGFβ) monoclonal antibody. This phase 1 clinical study investigates the safety, tolerability, and activity of a single dose of SAR439459 in adult participants with OI. Participants will receive a single IV dose of SAR439459 with safety, pharmacokinetic (PK), and pharmacodynamic (PD) assessments over 24 weeks. There will be up to 3 dose cohorts. In addition to safety, tolerability, and PK assessments, bone mineral density (BMD) will be eva... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/13/2024
Locations: UCLA Health_Site Number: 8400006, Los Angeles, California
Conditions: Osteogenesis Imperfecta
Register for Updates
Coronary Atherosclerosis T1-Weighted Characterization (CATCH)
NCT03504956
Recruiting
This study proposes to develop an MRI technique named Coronary Atherosclerosis T1-weighed Characterization (CATCH) that will improve the quality and reliability of coronary atherosclerosis evaluation, as well as simplify the scanning process and significantly shorten imaging time compared with conventional imaging methods.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Coronary Atherosclerosis
Register for Updates
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
NCT04067336
Recruiting
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess ziftomenib, a menin-MLL(KMT2A) inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase 1. In Phase 2, assessment of ziftomenib will continue in patients with NPM1-m AML.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: University of Southern California, Los Angeles, California +1 locations
Conditions: Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Mixed Phenotype Acute Leukemia
Register for Updates
IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML
NCT04372433
Recruiting
To assess safety and tolerability at increasing dose levels of IO-202 in successive cohorts of participants with AML with monocytic differentiation and CMML in order to estimate the maximum tolerated dose (MTD) or maximum administered dose (MAD) and select the recommended Phase 2 dose (RP2D)
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: UCLA, Medical Center Division of Hematology/Oncology (119), Los Angeles, California
Conditions: AML With Monocytic Differentiation, CMML
Register for Updates
Capillary Endoscopy Aspiration Catheter
NCT04418258
Recruiting
The small intestine is an understudied frontier of microbiome research. While aspiration during endoscopy is considered the gold standard to assess small bowel bacteria, the tools for sterile retrieval are primitive and poorly validated. Endoscopic aspiration is time-consuming and prone to contamination. Inspired by plants' ability to draw water by capillary action, a novel multi-capillary sterile system was designed which is a modified version of the conventional aspiration catheter. The purp... Read More
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
03/13/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Microbiota, SIBO
Register for Updates
Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD)
NCT05275686
Recruiting
Intranasal nasal steroid sprays are the mainstay of treatment for chronic Eustachian tube dysfunction despite having little supportive evidence in the literature. A novel, commercially available nasal spray delivery system is available now for fluticasone that improves its delivery to the nasopharynx. The hypothesis of this study is that fluticasone using the novel spray system is effective for Eustachian tube dysfunction (ETD).
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
03/13/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Eustachian Tube Dysfunction
Register for Updates
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
NCT03382977
Recruiting
The purpose of this study is to assess the safety and tolerability of VBI-1901 in subjects with recurrent malignant gliomas (glioblastoma, or GBM).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: University of California, Los Angeles Neuro-Oncology Program, Los Angeles, California
Conditions: Glioblastoma Multiforme
Register for Updates